Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)

BACKGROUND: This study aimed to evaluate the antitumor activity of camrelizumab, an antiprogrammed cell death-1 antibody, in pretreated recurrent or metastatic nasopharyngeal carcinoma (NPC) and to explore predictive biomarkers. METHODS: Patients with recurrent (not amenable to locally curative trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yunpeng, Zhou, Ting, Chen, Xiaozhong, Li, Jingao, Pan, Jianji, He, Xiaohui, Lin, Lizhu, Shi, Ying-rui, Feng, Weineng, Xiong, Jianping, Yang, Kunyu, Yu, Qitao, Zhang, Qunling, Hu, Desheng, Sun, Yan, Hu, Guangyuan, Li, Ping, Shen, Liangfang, Lin, Qin, Zhang, Ben, Qu, Xiao, Zou, Jianjun, Zhang, Li, Fang, Wenfeng, Zhao, Yuanyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693086/
https://www.ncbi.nlm.nih.gov/pubmed/34933967
http://dx.doi.org/10.1136/jitc-2021-003790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693086/
https://www.ncbi.nlm.nih.gov/pubmed/34933967
http://dx.doi.org/10.1136/jitc-2021-003790

Ejemplares similares